Previous 10 | Next 10 |
Do you, or did you, own shares of AlloVir, Inc. (NASDAQ:ALVR)? Did you purchase your shares between March 22, 2022 and December 21, 2023, inclusive? Did you lose money in your investment in AlloVir, Inc.? Do you want to discuss your rights? NEW YORK, NY / ACCESSWIRE / January ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 a...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 a...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In AlloVir To Contact Him Directly To Discuss Their Options If you suffered significant losses in AlloVir stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options ...
2023-12-05 08:55:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are penny stocks and then are penny stock picks that are so outrageously wild that they should never be considered unless one is gambling with pocket change. And by pocket change, I...
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference in New York City, NY on Tuesday, Novembe...
2023-11-02 11:37:32 ET More on AlloVir AlloVir: An Intriguing $3 Biotech Concern AlloVir slips after multiple insider sales AlloVir spikes as Bank of America starts at Buy on lead asset Seeking Alpha’s Quant Rating on AlloVir Historical earning...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
-- Posoleucel, a highly innovative off-the-shelf, multi-virus-specific investigational T cell therapy, continues to advance in three distinct, Phase 3, first-to-market indications in immunocompromised patients -- Enrollment in posoleucel pivotal Phase 3 multi-virus prevention, virus-assoc...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. Company Name:
ALVR Stock Symbol:
NASDAQ Market:
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...